ANTX — AN2 Therapeutics, Inc.
$3.55-2.47%
Last close: · regular session
Last 60 sessions
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for ANTX in the TickerWise workspace.
AN2 Therapeutics, Inc. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of treatments for uncommon, long-term, and severe infectious conditions. A key focus of their pipeline is epetraborole, an investigational oral medication designed for once-daily administration to individuals battling chronic non-tuberculous mycobacterial lung disease. This enterprise was established in 2017 and operates from its headquarters situated in Menlo Park, California.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ Global Select
- Employees: 22
- Website: https://www.an2therapeutics.com
Latest SEC filings for ANTX
Latest ANTX news
- SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of AN2 Therapeutics, Inc. (NASDAQ: ANTX) Read article
- AN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSK Read article
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.